All In Biotech

Free tool

FAERS Monitor: Azmiro

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 216318 or its brand name (Azmiro, Testosterone Cypionate). Reports on generic versions are filed under their own applications.

Reports

5,970

Serious

2,795

47% of reports

Hospitalization

1,248

Death reported

193

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective437
  • product dose omission issue384
  • fatigue369
  • off label use286
  • product deposit273
  • pain248
  • liquid product physical issue247
  • injection site pain240
  • poor quality product administered217
  • headache199
  • myocardial infarction187
  • nausea184
  • anxiety171
  • asthenia164
  • diarrhoea160

Reports by year received

View as table
YearReports
20043
20054
20065
20077
20085
200921
201018
201127
201239
201342
2014110
2015283
2016648
2017315
2018423
2019388
2020444
2021378
2022396
2023477
2024580
2025841
2026516

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,189 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
product depositSignal273748.4658.4167,493
liquid product physical issueSignal247123.5109.028,878
poor quality product administeredSignal21774.064.915,250
product dose omission issueSignal3844.64.21,094
myocardial infarctionSignal1873.83.3382
injection site painSignal2402.82.4271
anxietySignal1712.11.8101
fatigue3691.71.5102
asthenia1641.51.331
pain2481.41.332
drug ineffective4371.21.111
off label use2861.21.06
headache1991.11.02
diarrhoea1600.90.73
nausea1840.80.77

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.